This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Health Winners & Losers: ImClone

Health stocks were volatile following the broader markets and sentiment around the governments' financial bailout plan.

After a decent morning, the Nasdaq Biotechnology Index took a mid afternoon drop -- the biotech barometer was down 1.08, or 0.1%, at 834.04 in recent figures.

Late Monday, Bristol-Myers Squibb (BMY) increased its offer for ImClone (IMCL) to $62 a share, a 48% premium to the company's average trading price for the three months proceeding Bristol-Myers' $60-a-share bid made in early August. ImClone shares were up $3.14, or 5.3%, at $62.54, while Bristol edged down 42 cents, or 2%, to $20.20.

Genzyme (GENZ) gave a few calendar updates on Tuesday -- it expects the Food and Drug Administration to make a decision on its application for Myozyme at the 2000L bioreactor scale by Nov. 29. The company already has approval for Myozyme manufactured at the 160L bioreactor scale. An FDA advisory panel will meet on Oct. 21 to discuss proprietary manufacturing data and the clinical data that is the basis for the proposed label indication for the new scale of the product.

The company also said that the FDA has granted its Mozobil a priority review with a goal decision date of Dec. 16, and has a goal decision date of Dec. 23 for its Synvisc-One. Genzyme shares were off fractionally to $76.25.

A few analyst actions: Lazard Capital upgraded Valeant Pharmaceuticals (VRX) to hold from sell and increased its rating for Xenoport (XNPT) to buy from hold. Valeant was off fractionally and Xenoport was rising 1.4%.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Jim Cramer and Stephanie Link reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

Jim Cramer's protégé, David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
Try it NOW
Try it NOW
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

Jim Cramer's protégé, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 17,416.85 +225.48 1.31%
S&P 500 2,021.25 +19.09 0.95%
NASDAQ 4,683.4070 +45.4130 0.98%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs